Publications

Detailed Information

Tumor Size and Age Predict the Risk of Malignancy in Hurthle Cell Neoplasm of the Thyroid and Can Therefore Guide the Extent of Initial Thyroid Surgery

DC Field Value Language
dc.contributor.authorKim, Tae Hyuk-
dc.contributor.authorLim, Jung Ah-
dc.contributor.authorAhn, Hwa Young-
dc.contributor.authorLee, Eun Kyung-
dc.contributor.authorKim, Kyung Won-
dc.contributor.authorPark, Young Joo-
dc.contributor.authorKim, Kwang Hyun-
dc.contributor.authorCho, Bo Youn-
dc.contributor.authorYoun, Yeo Kyu-
dc.contributor.authorPark, Do Joon-
dc.contributor.authorChoi, Yun-Hee-
dc.contributor.authorMin, Hye Sook-
dc.date.accessioned2012-06-27T08:02:50Z-
dc.date.available2012-06-27T08:02:50Z-
dc.date.issued2010-11-
dc.identifier.citationTHYROID; Vol.20 11; 1229-1234ko_KR
dc.identifier.issn1050-7256-
dc.identifier.urihttps://hdl.handle.net/10371/77646-
dc.description.abstractBackground: The majority of patients having a diagnosis of Hurthle cell neoplasm (HCN) on fine-needle aspiration (FNA) of a thyroid nodule have a diagnostic thyroid lobectomy to make the final diagnosis. If the nodule is malignant, they require a completion thyroidectomy. The objective of this study was to devise a simple clinical scheme capable of predicting malignancy in patients with cytologic diagnosis of HCN and, therefore, guide the extent of initial thyroid surgery. Methods: A total of 57 patients who underwent thyroid surgery after an FNA diagnosis of HCN were retrospectively studied. The patients were examined for clinical features, preoperative imaging studies, and pathology reports. The risk of malignancy was calculated using a multiple logistic regression model. Results: The overall rate of malignancy in patients with HCN was 46% (26/57). The predictors of malignancy based on multiple logistic regression analysis were tumor size >1.5 cm (odds ratio [95% confidence interval] 8.0 [1.9-33.4]) and patient age >45 years (odds ratio [95% confidence interval] 2.3 [0.6-8.6]). In patients with nodules larger than 1.5 cm, the predicted probability of malignancy was greater in patients over 45 years than in younger patients (65% for >45 years vs. 44% for <= 45 years). In patients with a nodule 1.5 cm or less, the probability of malignancy was relatively low and not significantly different between the two age categories (18% for >45 years vs. 10% for <= 45 years). Conclusions: This study suggests that tumor size and age can be integrated into decision making for patients with an FNA diagnosis of HCN to facilitate patient selection for surgical referral and, particularly, to determine in which patients a thyroidectomy rather than a lobectomy should be the initial surgery.ko_KR
dc.language.isoenko_KR
dc.publisherMARY ANN LIEBERT INCko_KR
dc.titleTumor Size and Age Predict the Risk of Malignancy in Hurthle Cell Neoplasm of the Thyroid and Can Therefore Guide the Extent of Initial Thyroid Surgeryko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김태혁-
dc.contributor.AlternativeAuthor임정아-
dc.contributor.AlternativeAuthor안화영-
dc.contributor.AlternativeAuthor이은경-
dc.contributor.AlternativeAuthor민혜숙-
dc.contributor.AlternativeAuthor김경원-
dc.contributor.AlternativeAuthor최윤희-
dc.contributor.AlternativeAuthor박영주-
dc.contributor.AlternativeAuthor박도준-
dc.contributor.AlternativeAuthor김광현-
dc.contributor.AlternativeAuthor윤여규-
dc.contributor.AlternativeAuthor조보연-
dc.identifier.doi10.1089/thy.2009.0443-
dc.citation.journaltitleTHYROID-
dc.description.citedreferenceMontone KT, 2008, ARCH PATHOL LAB MED, V132, P1241-
dc.description.citedreferenceMoon WJ, 2008, RADIOLOGY, V247, P762, DOI 10.1148/radiol.2473070944-
dc.description.citedreferenceSippel RS, 2008, WORLD J SURG, V32, P702, DOI 10.1007/s00268-007-9416-5-
dc.description.citedreferenceWu HHJ, 2008, DIAGN CYTOPATHOL, V36, P149, DOI 10.1002/dc.20750-
dc.description.citedreferenceGRUBE E, 2007, INT J MED SCI, V4, P249-
dc.description.citedreferencePu RT, 2006, DIAGN CYTOPATHOL, V34, P330, DOI 10.1002/dc.20440-
dc.description.citedreferenceElliott DD, 2006, CANCER CYTOPATHOL, V108, P102, DOI 10.1002/cncr.21716-
dc.description.citedreferenceAlaedeen DI, 2005, SURGERY, V138, P650, DOI 10.1016/j.surg.2005.06.047-
dc.description.citedreferenceSchisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba-
dc.description.citedreferenceGiorgadze T, 2004, DIAGN CYTOPATHOL, V31, P307, DOI 10.1002/dc.20132-
dc.description.citedreferencePisanu A, 2004, WORLD J SURG, V28, P761, DOI 10.1007/s00268-004-7312-9-
dc.description.citedreferenceObuchowski NA, 2003, RADIOLOGY, V229, P3, DOI 10.1148/radiol.2291010898-
dc.description.citedreferenceLopez-Penabad L, 2003, CANCER, V97, P1186, DOI 10.1002/cncr.11176-
dc.description.citedreferenceYANG GC, 2003, ENDOCR PRACT, V9, P510-
dc.description.citedreferenceRenshaw AA, 2002, CANCER CYTOPATHOL, V96, P261, DOI 10.1002/cncr.10797-
dc.description.citedreferenceHundahl SA, 2000, CANCER, V89, P202-
dc.description.citedreferenceMcHenry CR, 1999, SURGERY, V126, P798-
dc.description.citedreferenceBaloch ZW, 1999, SEMIN DIAGN PATHOL, V16, P190-
dc.description.citedreferenceTuttle RM, 1998, THYROID, V8, P377-
dc.description.citedreferenceChen H, 1998, ANN SURG, V227, P542-
dc.description.citedreferenceHosmer DW, 1997, STAT MED, V16, P965-
dc.description.citedreferenceFaraggi D, 1996, STAT MED, V15, P2203-
dc.description.citedreferenceAPEL RL, 1995, AM J SURG PATHOL, V19, P810-
dc.description.citedreferenceONGPHIPHADHANAKUL B, 1992, ACTA ENDOCRINOL-COP, V126, P233-
dc.description.citedreferenceMCLEOD MK, 1990, OTOLARYNG CLIN N AM, V23, P441-
dc.description.citedreferenceLIVOLSI V, 1990, SURG PATHOLOGY THYRO-
dc.description.citedreferenceHEDINGER C, 1988, HISTOLOGIC TYPING TH-
dc.description.citedreferenceARGANINI M, 1986, SURGERY, V100, P1108-
dc.description.citedreferenceWATSON RG, 1984, MAYO CLIN PROC, V59, P851-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share